Congenica raises £39m in a Series C round co-led by Tencent and Legal & General to advance genomic software.
The financing round was co-led by Tencent and Legal & General to support international expansion and product development.
Congenica develops genomic analysis software for interpreting complex data related to rare diseases and inherited cancer. The company serves a global customer base of hospitals, laboratories, and pharmaceutical companies across multiple continents.
Cambridge-based digital health firm Congenica has raised £39m in a Series C funding round to accelerate its international expansion and broaden its product offerings. The investment was co-led by Tencent and Legal & General, with participation from several new and existing backers.
The capital will support the commercialisation of the company platform across rare disease and inherited cancer diagnostics, alongside new applications in oncology and wellness. Additional funds will target pharmaceutical collaborations and integration capabilities with existing electronic health systems.
The financing brings strategic and geographic advantages as the company builds on its established footprint. Lazard acted as sole financial advisor to the transaction.
From the founder
"Genomic medicine is revolutionising healthcare, transforming outcomes for patients by providing clinicians with fast, accurate and early diagnoses and the information needed to provide life-changing answers for their patients, improving wellbeing and disease management. This new funding will allow us to build on our established foundation in rare disease and bring the power of our platform to new indications and new markets. We welcome our new investors to Congenica and are grateful to our existing investors for their continued support."
David Atkins
Chief Executive Officer at Congenica
Investor perspective
"Congenica’s market leading technology is designed to enable the delivery of personalised medicine at scale and be fully integrated into routine healthcare customers’ clinical practice on a global basis. This represents a significant competitive advantage and the potential to bring genomic medicine into routine use across multiple disease areas driving healthcare systems internationally. We look forward to supporting Congenica as it continues to find innovative solutions to transform healthcare"
Ling Ge
Chief European Representative, Tencent
Use of funds
- 01Expand into international markets
- 02Continue product development
Investors
Ling Ge
Tencent
Jessica McCreadie
Legal & General
Xeraya
Puhua Capital
IDO Investments
Parkwalk
Cambridge Innovation Capital
Downing
